This study will evaluate the clinical efficacy and safety of udenafil, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of adolescent who have had the Fontan procedure.

开始日期2023-10-30

申办/合作机构

Mezzion Pharma Co., Ltd.

KCT0005833

/ Completed临床4期IIT

Effect of Udenafil Administration for Blood Flow Increase in the Prefrontal Cortex

开始日期2020-12-01

申办/合作机构-

NCT03430583

/ Completed临床3期

Imaging and Biomarker Evaluation of Hepatic Stiffness in Children Enrolled in the Fontan Udenafil Exercise Longitudinal Study

A study to evaluate the efficacy of MZ101 therapy in reducing liver stiffness.

开始日期2018-02-20

申办/合作机构

Mezzion Pharma Co., Ltd.

[+1]

100 项与乌地那非相关的临床结果

登录后查看更多信息

100 项与乌地那非相关的转化医学

登录后查看更多信息

100 项与乌地那非相关的专利（医药）

登录后查看更多信息

217

项与乌地那非相关的文献（医药）

2026-04-30·NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

An integrative machine learning and structure-driven drug repositioning strategy for human IRAK4-targeted cancer therapy.

Article

作者: Shen, Xiaolin ; Raza, Muhammad Ali ; Ahmad, Muneer ; Iqbal, Muhammad Waleed ; Sun, Xinxiao ; Lv, Jianlong

The upregulation of interleukin-1 receptor-associated kinase 4 (IRAK4) drives pro-tumorigenic signaling across various malignancies. Currently available IRAK4 inhibitors are all limited by suboptimal selectivity and off-target toxicity. To develop non-toxic and mechanistically focused IRAK4 inhibitors, an in silico machine learning (ML) pipeline combined with structure-driven drug repositioning was employed. An IRAK4-targeting dataset of bioactive compounds was systematically filtered and curated to train a random forest (RF) regression model. Comparative cross-validation against 41 independent ML frameworks demonstrated reasonable predictive accuracy, and the optimized model was deployed to screen a library of 1040 FDA-approved therapeutics. Orthogonal molecular docking supported the binding efficacy of RF-identified lead compounds, including udenafil, linagliptin, benflumetol, and nimodipine. Thermodynamic and conformational stability were validated using molecular dynamics (MD) simulations, yielding stable root mean square deviation (RMSD), radius of gyration (R_g), root mean square fluctuation (RMSF), principal component analysis (PCA), hydrogen bonding, and MMGBSA/MM-PBSA profiles. The efficacy of these candidates was further supported by their low toxicity profiles, via graph neural network (GNN)-based toxicity analysis. These findings establish a scalable computational strategy for identifying repurposable oncology therapeutics and propose udenafil, linagliptin, benflumetol, and nimodipine as mechanistically credible candidates for experimental validation.

2025-08-19·Journal of the American Heart Association

Revisiting the Effect of Udenafil on Exercise Performance in Patients With Fontan Circulation: Results of a Post Hoc Analysis of the FUEL Trial

Article

作者: Goldberg, David J. ; Orr, William B. ; Nowlen, Todd T. ; Ploutz, Michelle ; Frischhertz, Benjamin P. ; DiMaria, Michael V. ; McCrindle, Brian W. ; Lubert, Adam M. ; Cartoski, Mark J. ; Goldstein, Bryan H. ; McHugh, Kimberly E. ; Penny, Daniel J. ; Garg, Ruchira ; Zak, Victor ; Ginde, Salil ; Schumacher, Kurt R. ; Yauck, Jennifer S. ; Whitehill, Robert ; Mackie, Andrew S. ; Davis, Christopher K. ; Yetman, Anji T. ; Rathod, Rahul H. ; Wagner, Jonathan B. ; Kim, Gi Beom ; Payne, R. Mark ; Paridon, Stephen M. ; Pearson, Gail D. ; McBride, Michael G. ; Yeager, James ; Hill, Kevin D. ; Hu, Chenwei ; Richmond, Marc E. ; Detterich, Jon ; John, Anitha S. ; Files, Matthew

Background:

In the FUEL (Fontan Udenafil Exercise Longitudinal) trial, a positive treatment effect was identified for outcomes at the ventilatory anaerobic threshold but not for the primary outcome, oxygen consumption (V o2 ) at peak exercise. This disparate response may be explained by the physiologic challenge of improving peak V o2 in participants with near‐normal baseline exercise performance.

Methods:

Participants were divided into subgroups by baseline predicted peak V o2 (<80% versus ≥80%). Treatment effect was evaluated in those with a baseline peak V o2 <80% predicted and linear regression was performed to examine the interaction between subgroup and response to therapy for the primary and secondary outcomes.

Results:

Of the 379 participants with paired exercise data, 302 (80%) had a baseline peak V o2 <80% predicted. In this subgroup, the primary outcome of peak V o2 improved significantly after 6 months of udenafil treatment, when compared with placebo (0.23±4.17 mL/kg per min versus −0.90±3.74 mL/kg per min; P =0.021). Secondary outcome measures, including V o2 at ventilatory anaerobic threshold ( P =0.023), work at ventilatory anaerobic threshold ( P =0.032), and the myocardial performance index ( P =0.007) were all significantly improved as well. A significant interaction was found between exercise subgroups and response to udenafil for peak V o2 ( P =0.036) but not for other outcomes.

Conclusions:

In this post hoc subgroup analysis, after exclusion of patients with Fontan circulation with near‐normal baseline peak V o2 , a positive treatment effect of udenafil was identified for the primary outcome of peak V o2 . The interaction between baseline peak V o2 and treatment may have influenced the outcome of the FUEL trial.

Registration:

URL: https://clinicaltrials.gov ; Unique identifier: NCT0274115.

2025-04-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Identification of Phosphodiesterase type 5 inhibitors (PDE5is) analogues using surface-enhanced Raman scattering and machine learning algorithm

Article

作者: Huang, Jiadong ; He, Hongyuan ; Li, Yujing ; Luan, Yujing

Phosphodiesterase type 5 inhibitors (PDE5is), primarily used for the treatment of erectile dysfunction, have been severely misused in recent years, posing a threat to public health and safety. This study developed a method that combines Surface-enhanced Raman spectroscopy (SERS) with machine learning algorithms to rapidly identify different PDE5is types. A total of 948 SERS spectra from 79 PDE5is were collected using gold nanoparticles (AuNPs) as the enhancement agent, and dimensionality reduction was performed through principal component analysis (PCA). Subsequently, six traditional machine learning models, partial least squares discriminant analysis (PLS-DA), orthogonal partial least squares discriminant analysis (OPLS-DA), support vector machines (SVM), k-nearest neighbors (KNN), random forest (RF), and multilayer perceptron (MLP) were applied for data classification and identification. Results showed that the MLP model achieved the highest classification accuracy of 99.65 %, with only 1.82 % of the samples misclassified from thiosildenafil to sildenafil analogues, significantly outperforming the other models. This method offers a rapid, cost-effective, and accurate alternative for the detection of PDE5is in health foods, with implications for improving regulatory oversight and public health safety.

项与乌地那非相关的新闻（医药）

2026-07-16

·PRNewswire

FUEL FALD Study Published in Pediatric Cardiology

Peer-reviewed publication advances understanding of Fontan-associated liver disease (FALD) and adds to the growing body of evidence supporting udenafil in Fontan circulation FORT LEE, N.J., July 16, 2026 /PRNewswire/ -- Mezzion Pharmaceuticals today announced publication of "The FUEL FALD Study: Effects of Udenafil on Liver Stiffness and Fibrosis after Fontan" in the peer-reviewed journal Pediatric Cardiology. The publication reports findings from an exploratory substudy of the FUEL Open Label Extension (OLE) evaluating Fontan-associated liver disease (FALD) in adolescents and young adults who received 12 months of udenafil treatment. As survival following the Fontan procedure has improved, FALD has emerged as one of the most important long-term complications affecting patients living with Fontan circulation. Driven by the unique Fontan physiology, FALD is characterized by progressive liver injury and fibrosis and remains an area of significant unmet medical need, with no approved therapies specifically indicated for this condition. The publication highlights the substantial burden of liver disease in this population. At study entry, 95% of participants had elevated Enhanced Liver Fibrosis (ELF) scores, consistent with at least moderate fibrosis based on thresholds established in other liver diseases. Liver stiffness was also assessed using ultrasound shear wave elastography (SWE) and magnetic resonance elastography (MRE) . Following 12 months of udenafil treatment, investigators observed a significant decrease in the ELF score, a non-invasive biomarker associated with fibrotic remodeling, with 84% of participants demonstrating a reduction over the study period. Although liver stiffness measurements did not significantly change, the authors concluded that the findings suggest the possibility that udenafil may alter the overall Fontan fibrotic milieu and warrant further study. The publication adds to a growing body of peer-reviewed evidence from the FUEL clinical program examining udenafil across multiple dimensions of Fontan physiology, including exercise capacity, ventricular performance, cardiovascular safety, nitric oxide pathway biology, patient experience, and liver fibrosis biomarkers. "As patients with Fontan circulation continue to live longer, understanding and addressing the long-term complications of Fontan physiology has become increasingly important," said Kurt Schumacher, M.D., Chief of Pediatric Cardiology at University of Michigan Health C.S. Mott Children's Hospital and lead author of the publication. "These findings contribute to our growing understanding of Fontan-associated liver disease and reinforce the importance of continuing to investigate therapies that may address this serious long-term complication." "Fontan-associated liver disease is one of the most serious long-term complications of Fontan circulation, and patients and clinicians have very limited options to address it." said Ridwan Shabsigh, M.D., F.A.C.S, President and COO of Mezzion, "The FUEL FALD Study provides important new insight into the potential role of udenafil in the fibrotic process associated with Fontan physiology and supports continued investigation of this complex disease." "The breadth of research emerging from the FUEL program is providing increasingly comprehensive view of Fontan physiology and the potential role of udenafil," said Dean Park, Chairman and CEO of Mezzion. " As we advance through the final phase of enrollment in the confirmatory Phase 3 FUEL-2 trial, we remain focused on developing the first therapy specifically indicated for patients living with Fontan circulation." Mezzion gratefully acknowledges the patients and families who participated in the FUEL clinical program, the investigators and participating clinical sites, and the Pediatric Heart Network for their contributions to advancing research in Fontan circulation. About the FUEL-2 Trial FUEL-2 is Mezzion's global confirmatory Phase 3 trial evaluating udenafil in adolescents and young adults with Fontan circulation. The study is designed to evaluate exercise capacity and support potential regulatory approval of udenafil as the first therapy specifically developed for patients living with Fontan circulation. Learn more at . Publication The full publication is available in Pediatric Cardiology: About Mezzion Pharmaceuticals Mezzion Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for rare cardiovascular and renal diseases. Its lead investigational product, udenafil, is being evaluated in the global Phase 3 FUEL-2 trial for single ventricle congenital heart disease patients living with Fontan circulation. Mezzion Pharmaceuticals is the U.S. subsidiary of Mezzion Pharma Co., Ltd. (KOSDAQ: 140410). Learn more at . Forward-Looking Statements This press release contains forward-looking statements regarding the future development of Mezzion's investigational product candidates, including statements relating to the clinical development of udenafil, the FUEL-2 trial, regulatory interactions, potential regulatory approvals, future research, and anticipated clinical outcomes. These forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Mezzion undertakes no obligation to update any forward-looking statements except as required by applicable law. Media & Investor Contacts John Presser Executive Vice President & Chief Business Officer [email protected] Sung-Il Noh Chief Financial Officer [email protected] SOURCE Mezzion Pharmaceuticals, Inc 21% more press release views with Request a Demo

临床3期临床结果

2026-06-05

·PRNewswire

Mezzion Pharma Completes FUEL-2 Phase 3 Regulatory Milestone

After independent review, study continues as planned with enrollment on track for completion in 2026 SEOUL, South Korea and FORT LEE, N.J., June 5, 2026 /PRNewswire/ -- Mezzion Pharma Co., Ltd. (KOSDAQ: 140410) today announced the results of a planned independent, blinded statistical review of its ongoing global confirmatory Phase 3 FUEL-2 study evaluating udenafil, its investigational therapy for single ventricle heart disease with Fontan circulation. After 50% of the planned study population completed the study's 26-week treatment period, an independent assessment was conducted to determine whether an increase in sample size would be required to maintain the study's planned statistical assumptions. The independent review determined that no increase in sample size was required and recommended that the study continue as planned with the enrollment of 436 patients. Moreover, no changes were recommended to the study design, primary endpoint, statistical analysis plan, or projected study timelines. "We believe the successful completion of this independent review marks an important milestone for the FUEL-2 program," said Dean Park, Chairman and CEO of Mezzion Pharma. "We remain focused on advancing udenafil toward becoming the first approved therapy specifically indicated for patients with single ventricle heart disease with Fontan circulation." Mezzion Pharma has now completed all major planned statistical review milestones prior to topline data. Single ventricle heart disease with Fontan circulation is a rare and serious form of congenital heart disease associated with significant long-term complications. Despite advances in surgical care, there are currently no approved therapies specifically indicated for this rare disease with unmet medical need. About Mezzion Pharma Mezzion Pharma Co., Ltd. (KOSDAQ: 140410) is a late-stage biopharmaceutical company focused on developing therapies for rare cardiovascular and renal diseases. Its lead program, udenafil, is being developed as a potential first therapy specifically indicated for patients with Fontan circulation. Udenafil is an investigational product and has not been approved by any regulatory authority. Mezzion conducts its U.S. operations through its wholly owned subsidiary, Mezzion Pharmaceuticals, Inc. For more information, visit mezzion.com or FUEL2Study.com. Forward-Looking Statements This press release contains forward-looking statements regarding future events and the future performance of Mezzion Pharma, including statements regarding clinical development timelines, regulatory activities, potential approval of udenafil, and anticipated study outcomes. Actual results may differ materially from those expressed or implied by these forward-looking statements. Mezzion undertakes no obligation to update any forward-looking statements except as required by applicable law. Media Contacts: John Presser, EVP, CBO: [email protected] Mr. Sung-Il Noh, CFO: [email protected] SOURCE Mezzion Pharma Co., Ltd. 21% more press release views with Request a Demo

临床3期

2026-05-26

·临港科创投资

【5月26日临科创投资晨报】美国匿名官员透露，美国和伊朗的框架协议目前“已达成95%”

长按扫码临科创投资投资可预见的未来以下市场资讯由临科创投资研究所整理摘要 1、宏观经济与政策：美国匿名官员透露，美国和伊朗的框架协议目前“已达成95%”，双方在伊朗“核储备”和霍尔木兹海峡问题上达成协议，目前正在就“措辞”进行磋商。这名官员否认了美国很快与伊朗达成协议的可能性，推测美国总统特朗普可能给美伊双方谈判代表5到7天时间来达成协议，如果未能达成协议，美国“可以恢复军事打击”。伊朗外交部发言人巴加埃表示，伊朗和美国已就大部分问题达成共识，但“这并不意味着即将签署协议”。当前美国和伊朗间谈判的重点是结束战争，现阶段并未讨论核问题。 2、市场跟踪： ◇周一（5月25日）A股放量上攻，半导体产业链核心爆发，个股迭创新高，科创50大涨近6%。上证指数收涨0.96%报4152.57点，深证成指涨1.66%，创业板指涨2.1%，北证50跌0.79%，科创50涨5.88%，万得全A涨1.21%。A股全天成交3.23万亿，上日成交2.92万亿。半导体产业链大涨，东芯股份、华虹公司等多股收获20cm涨停，兆易创新、寒武纪大涨创历史新高。煤炭股表现不俗，盘江股份、淮北矿业、平煤股份涨停。中国台湾加权指数收涨3.26%，报43644.4点，再创历史新高，年内累计涨幅达50.69%。半导体板块大涨，台积电涨超2%，联发科涨约10%，台达电涨超9%，鸿海涨超4%。港股今日因佛诞翌日休市一日，南、北向交易关闭。 ◇5月26日，Shibor隔夜品种报1.3270%，1个月期报1.3920%。 ◇5月26日，人民币对美元中间价报6.7835。周一（5月22日）因阵亡将士纪念日，美国股市周一休市一日。美债收益率集体下跌，2年期美债收益率跌8.72个基点报4.034%，3年期美债收益率跌9.90个基点报4.078%，5年期美债收益率跌11.24个基点报4.156%，10年期美债收益率跌11.27个基点报4.463%，30年期美债收益率跌9.59个基点报4.991%。国际贵金属期货普遍收涨，COMEX黄金期货涨1.11%报4573.6美元/盎司，COMEX白银期货涨2.89%报78.4美元/盎司。美国和伊朗即将达成停火协议的消息提振市场情绪，预期霍尔木兹海峡将重新开放，导致国际油价大跌超5%，通胀担忧随之降温。同时，美元指数走低，为黄金和白银等无息资产提供了估值支撑。 3、投融资速递：5月25日，焕星科技完成新一轮融资、拓微新材获得A轮融资、博迪贺康完成A轮融资、一起数商完成1000万元人民币天使轮融资、Stitch.co获得2500万美元A轮融资、Wonderlab Bio获得战略投资、Optura获得1750万美元A轮融资、Mezzion获得战略投资、XORTX获得500万美元战略投资 4、【园区动态】OPCX2026展商介绍①丨灵感在此生长，动力向此汇聚！晨报内容一、宏观经济与政策二、每日市场跟踪三、投融资速递四、园区动态壹宏观经济与政策美国匿名官员透露，美国和伊朗的框架协议目前“已达成95%”，双方在伊朗“核储备”和霍尔木兹海峡问题上达成协议，目前正在就“措辞”进行磋商这名官员否认了美国很快与伊朗达成协议的可能性，推测美国总统特朗普可能给美伊双方谈判代表5到7天时间来达成协议，如果未能达成协议，美国“可以恢复军事打击”。伊朗外交部发言人巴加埃表示，伊朗和美国已就大部分问题达成共识，但“这并不意味着即将签署协议”。当前美国和伊朗间谈判的重点是结束战争，现阶段并未讨论核问题。在电气电子工程师学会（IEEE）在上海举办的国际电路与系统研讨会上，华为公司发表“韬(τ)定律”，提出以“时间(τ)缩微”替代“几何缩微”，作为半导体与电子系统演进的新指导原则通过逻辑折叠等创新技术，持续压缩信号传播时延，不断提升晶体管密度，从而实现半导体与电子系统的持续演进。华为公司预计，到2031年，基于韬(τ)定律的高端芯片晶体管密度有望达到1.4纳米制程的同等水平。这也是中国在全球半导体领域首次提出指导产业发展的新原则。人社部等5部门对外发布《超龄劳动者基本权益保障暂行规定》，自7月1日起施行这是我国首部明确超龄劳动者权益的专门规章，填补了我国现行劳动法律制度的短板，明确了用人单位与超龄劳动者的权利和义务，保障超龄劳动者的劳动报酬、休息休假、劳动安全卫生、工伤保障等合法权益。海南省商务厅等五部门近期出台的《海南省促进城市商业提质升级若干措施》明确了完善网络布局、推动业态创新、丰富优质商品供给、强化运行保障、优化空间利用五大方面举措，包括打造国际消费核心引擎商圈、建设文旅商融合特色消费街区、构筑自贸港汽车全链消费高地等十七条措施。贰每日市场跟踪 A.股市行情名称最新涨幅% 年初至今涨幅% 上证综指 4152.57 0.96 4.63 深证成指 15856.61 1.66 17.24 沪深300 4921.60 1.58 6.30 科创50 1896.04 5.88 41.05 创业板指 4021.16 2.10 25.54 恒生指数 25606.03 0.86 -0.10 道琼斯工业 50579.70 0.58 5.24 纳斯达克指数 26343.97 0.19 13.35 标普500 7473.47 0.37 9.17 A股放量上攻，半导体产业链核心爆发，个股迭创新高，科创50大涨近6%。上证指数收涨0.96%报4152.57点，深证成指涨1.66%，创业板指涨2.1%，北证50跌0.79%，科创50涨5.88%，万得全A涨1.21%。A股全天成交3.23万亿，上日成交2.92万亿。半导体产业链大涨，东芯股份、华虹公司等多股收获20cm涨停，兆易创新、寒武纪大涨创历史新高。煤炭股表现不俗，盘江股份、淮北矿业、平煤股份涨停。中国台湾加权指数收涨3.26%，报43644.4点，再创历史新高，年内累计涨幅达50.69%。半导体板块大涨，台积电涨超2%，联发科涨约10%，台达电涨超9%，鸿海涨超4%。港股今日因佛诞翌日休市一日，南、北向交易关闭。 B.债市行情期限 Shibor(%) 涨跌(BP) O/N 1.3270 0.23 1W 1.4010 2.64 2W 1.4070 2.55 1M 1.3920 0.29 5月26日，Shibor隔夜品种报1.3270%，1个月期报1.3920%。 C.重要外汇名称最新涨幅% 年初至今涨幅% 美元中间价 6.7835 -0.02 -2.87 欧元中间价 7.8979 -0.03 -3.35 日元中间价 4.2690 -0.10 -4.00 英镑中间价 9.1534 0.04 -2.47 港币中间价 0.8658 -0.01 -3.34 5月26日，人民币对美元中间价报6.7835。叁投融资速递 A. 国内事件焕星科技完成新一轮融资焕星科技是一家以再生材料为核心技术的生物科技公司。公司目前有可吸收高分子材料、医美、可吸收缝合线三大业务板块，依托自主研发的可吸收高分子原料及微球制备工艺，在医美、可吸收缝合线等下游应用板块取得高速发展。近日，焕星科技宣布完成新一轮战略股权融资。本轮融资由国内上市公司通鼎集团战略投资，所募资金将用于超高分PGA工业高端应用研发、新型可吸收手术缝合线产能扩张及全球化市场推广，助力焕星科技夯实可吸收高分子材料全产业链优势，加速医疗、工业、医美多场景产业化落地。拓微新材获得A轮融资拓微新材是一家合成生物学技术创新平台型企业，产品矩阵涵盖高端尼龙材料、可降解材料和药物中间体等。近日，拓微新材获得A轮融资，中启资本投资。博迪贺康完成A轮融资博迪贺康是一家致力于创新型Treg（调节性T细胞）免疫治疗的生物制药公司，小分子化药与细胞沿线并行推进，聚焦自身免疫性疾病和炎性疾病领域。近日，博迪贺康完成A轮融资，由复旦科创与龙磐投资联合领投。本轮融资将主要用于核心管线BT-101的一期临床试验，并推进细胞治疗管线的临床前研究，旨在加速其创新型免疫耐受重建疗法从实验室走向临床应用，为全球自身免疫性疾病患者带来突破性治疗方案。一起数商完成1000万元人民币天使轮融资一起数商是一家全品类数字化商业服务平台，聚焦酒水、茶叶、农产品赛道，打造合规数字资产营销工具，依托区块链与国有文交所监管体系，助力实体商家降本增效、提升动销。投资方表示，将以资本、资源、渠道全面赋能，共同推动数实融合深度发展。近日，一起数商完成1000万元人民币天使轮融资，由香港和洛恒盈产业科技集团有限公司独家战略投资。本轮融资为公司首轮外部融资，资金将用于数实融合产品研发、技术攻坚、市场拓展及团队建设，加速商业化落地与全国布局。 B. 国外事件 Stitch.co获得2500万美元A轮融资 Stitch.co是一家金融科技服务商，为银行、消费金融、支付公司提供统一金融核心操作系统，提供统一账本、借贷、发卡、支付、存款服务。近日，Stitch.co获得2500万美元A轮融资，Andreessen Horowitz-a16z领投，Arbor Ventures乔木创投、COTU Ventures、Raed Ventures、SVC参投。 Wonderlab Bio获得战略投资 Wonderlab Bio是一家细胞疗法研究商，旨在弥补医学领域最长期存在的空白之一。细胞疗法可以修复受损组织，逆转退行性疾病，恢复功能。近日，Wonderlab Bio获得战略投资。 Optura获得1750万美元A轮融资 Optura是一家企业医疗平台，将领导优先事项转化为直接基于现有工作流程和标准操作程序构建的运营人工智能代理，在投入资金前模拟回报，并在统一的智能层上跟踪实时表现与预测。ROAI™是用可衡量表现取代无方向AI试点的学科，为医疗领导者如何证明、资助和管理AI投资树立了现代标准。近日，Optura获得1750万美元A轮融资，Echo Health Ventures、Susa Capital、Matrix Partners经纬海外、HC9 Ventures、Salesforce投资。 Mezzion获得战略投资 Mezzion是一家罕见病口服创新药研发商，专注于单心室先天性心脏病患者和Fontan循环系统的治疗。Mezzion正在开发JURVIGO®（udenafil）作为单心室先天性心脏病和Fontan生理学患者的潜在首选治疗方法。近日，Mezzion获得战略投资。 XORTX获得500万美元战略投资 XORTX是一家肾脏疾病治疗药物研发商，开发了两种临床先进的产品：XRx-008用于治疗自体显性多囊性肾脏疾病（ADPKD）；XRx-101用于治疗冠状病毒 /COVID-19 感染。XRx-225是用于治疗2型糖尿病肾病（T2DN），目前处于临床前开发阶段。XORTX 正在努力推进其临床开发阶段产品，该产品针对异常的纯代谢和氧化酶，以减少或抑制尿酸的生产。近日，XORTX获得500万美元战略投资。查看详情肆园区动态南港码头两项指标创月度新高，国产汽车加速“出海” 2026上海超级个体（OPC）经济大会暨零界魔方焕新生态发布会（简称：OPCX 2026）是国内率先聚焦超级个体（OPC）经济的产业盛会，由临港新片区管委会、上海市经济信息化委、上海市文创办指导，临港集团和解放日报社联合主办。大会致力于打造集“创新成果展示、优质资源对接、创意社群链接”于一体的OPC集聚平台，不仅全方位展现OPC经济的创新活力与产业势能，更着力打通产业链、供应链和创新链，推动OPC创业者从“原子化生存”向“生态化协同”跃升。展区以“未来生活体验场，超松弛灵感创意源”为主题，打造了一座集互动街区、科技乐园、草坪音乐会于一体的沉浸式体验空间。这里没有冷冰冰的展台，只有好玩、好逛、好出片的自由氛围。你可以亲手把玩AI玩具，在科技装置前拍下酷炫合影，或者干脆躺在草坪上，让音乐接管所有疲惫。逛累了？现场还有Eva Cafe & Pizzeria、星巴克、优必喜、优传酒业等零界魔方入驻的餐饮品牌，为大会提供从咖啡轻食到品质简餐的全时段补给。一杯咖啡就能聊出一个新的合作灵感。展区以“OPC生态赋能中枢，硬核生产力集中秀场”为核心，集中展示临港新片区为超级个体搭建的“动力引擎矩阵”。这里不是炫技的舞台，而是真正能把想法落地的资源库。从国有产业平台、商业银行到AI算力巨头，从硬科技孵化器到跨境供应链服务商……他们带来的是资金、算力、办公空间、产业对接、创业辅导等“超级个体”最需要的“弹药”。无论缺钱、缺人、缺技术，还是缺一个被看见的机会，在这里都有可能找到托起梦想的那双手。

100 项与乌地那非相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10027	乌地那非	G04BE11	DB06267

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
勃起功能障碍	韩国	Dong-A Pharmaceutical Co., Ltd.	2005-11-29

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
单心室心脏	临床3期	美国	Mezzion Pharma Co., Ltd.	2016-07-22
单心室心脏	临床3期	加拿大	Mezzion Pharma Co., Ltd.	2016-07-22
单心室心脏	临床3期	韩国	Mezzion Pharma Co., Ltd.	2016-07-22
肺动脉高压	临床3期	韩国	Dong-A ST Co., Ltd.	2014-04-01
阿尔茨海默症	临床3期	韩国	Dong-A Pharmaceutical Co., Ltd.	2013-09-01
射血分数保留型心力衰竭	临床3期	韩国	Dong-A Pharmaceutical Co., Ltd.	2012-10-01
舒张期心力衰竭	临床3期	韩国	Dong-A Pharmaceutical Co., Ltd.	2012-10-01
特发性肺动脉高压	临床3期	韩国	Dong-A Pharmaceutical Co., Ltd.	2012-09-01
门静脉高血压	临床3期	奥地利	Dr. Falk Pharma GmbH	2012-04-04
肝硬化	临床3期	奥地利	Dr. Falk Pharma GmbH	2012-04-04

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03013751 (FUELExten, CTgov)	临床3期	单心室心脏	301	Udenafil (In PHN-Udenafil-02 (FUEL) Received Udenafil)	廠製顧築鏇鏇壓窪醖觸(鑰醖製蓋簾壓顧願願網) = 憲積廠範醖積蓋鑰艱壓廠衊廠艱網餘範醖觸構 (遞艱鑰膚鹹獵簾醖獵鏇, 470.80) 更多	-	2025-12-09
				Udenafil (In PHN-Udenafil-02 (FUEL) Received Placebo)	廠製顧築鏇鏇壓窪醖觸(鑰醖製蓋簾壓顧願願網) = 遞鹽構鑰網壓憲築衊糧廠衊廠艱網餘範醖觸構 (遞艱鑰膚鹹獵簾醖獵鏇, 444.26) 更多
NCT03430583 (FALD, CTgov)	临床3期	单心室心脏	88	Udenafil (Udenafil Continuation (U+))	醖積餘積鹹膚觸壓糧範(醖鑰選淵憲選廠憲觸襯) = 網夢醖築餘夢遞蓋遞餘艱糧廠選鬱範鏇齋夢鏇 (衊糧壓蓋繭鏇積選膚壓, 0.380) 更多	-	2025-09-18
				Udenafil (Udenafil Naive (U-))	醖積餘積鹹膚觸壓糧範(醖鑰選淵憲選廠憲觸襯) = 鬱觸艱範築簾選鑰觸餘艱糧廠選鬱範鏇齋夢鏇 (衊糧壓蓋繭鏇積選膚壓, 0.450) 更多
NCT02741115 (FUEL, CTgov)	临床3期	单心室心脏	400	Placebo (Placebo)	膚製願艱觸衊築範鹽鏇(選網艱窪鬱憲鑰膚衊餘) = 壓鏇觸廠齋窪廠夢網壓遞鏇膚鹹願鹽獵餘膚觸 (醖膚醖範憲願獵顧積觸, 3.672) 更多	-	2025-05-21
				Udenafil (Drug)	構構艱糧選製鬱醖齋糧(鑰鹽淵製膚範廠願繭鹽) = 蓋願鬱獵餘製襯網憲蓋憲製衊壓艱蓋構襯膚淵 (淵鹹壓鏇廠積糧顧艱襯, 0.112) 更多
NCT01553721 (Pubmed \| Clin Ther)	临床2期	肺动脉高压	63	Udenafil 50-mg	鑰積選觸構遞齋膚鑰壓(醖蓋齋積鹹夢蓋鹹膚選) = 糧繭憲夢顧廠鏇鹹醖廠觸壓鏇廠壓鬱網範餘選 (壓範憲積膚壓積鹹顧鬱 )	积极	2019-08-01
NCT01553721 (Pubmed \| Korean Circ J)	临床2期	肺动脉高压	63	Udenafil 50 mg	齋鏇顧積蓋艱壓顧夢築(蓋鬱築顧構願膚製選遞) = 鑰艱夢遞憲醖壓願願淵積壓糧顧鏇選醖遞鏇窪 (夢廠衊餘衊淵膚鬱製繭 ) 更多	-	2019-04-01
				Udenafil 100 mg	齋鏇顧積蓋艱壓顧夢築(蓋鬱築顧構願膚製選遞) = 淵艱膚簾蓋範襯遞糧壓積壓糧顧鏇選醖遞鏇窪 (夢廠衊餘衊淵膚鬱製繭 ) 更多
KCT0001436 (Pubmed \| J Clin Pharmacol)	临床1期	-	-	Udenafil (Healthy young men (21-27 years))	鬱鏇獵鹽憲廠構餘衊窪(齋膚鏇鏇鬱獵醖築遞繭) = 壓遞鏇壓艱窪衊憲憲餘壓鏇鬱顧艱鏇鏇艱願獵 (簾簾糧繭齋淵壓鑰膚襯 ) 更多	-	2016-11-01
				Udenafil (Healthy elderly men (65-78 years))	鬱鏇獵鹽憲廠構餘衊窪(齋膚鏇鏇鬱獵醖築遞繭) = 壓築選襯憲簾鹹築鬱糧壓鏇鬱顧艱鏇鏇艱願獵 (簾簾糧繭齋淵壓鑰膚襯 ) 更多
NCT01280266 (EULAR2014)	临床2/3期	雷诺病	12	Udenafil 100 mg/day	顧憲鬱繭獵醖膚鏇鏇鹽(鹹鏇鹹簾願鬱築範鏇鹽) = 壓膚製鏇淵齋繭窪獵餘觸鹹廠鹽窪鹽構構醖餘 (簾膚製簾鏇鬱繭衊製餘 ) 更多	-	2014-06-11
NCT01280266 (CTgov)	临床2/3期	雷诺病	29	Amlodipine (Amlodipine)	鏇繭製觸襯繭窪鹹鹹繭(鑰蓋糧餘築鑰顧願餘獵) = 鑰壓築繭夢鹹網鹽壓網製選齋憲齋淵顧襯築鬱 (淵積壓窪艱願製餘餘鹽, 1.4) 更多	-	2012-12-11
				Udenafil (Udenafil)	鏇繭製觸襯繭窪鹹鹹繭(鑰蓋糧餘築鑰顧願餘獵) = 獵簾觸醖願淵製艱蓋糧製選齋憲齋淵顧襯築鬱 (淵積壓窪艱願製餘餘鹽, 0.9) 更多
NCT01364181 (Pubmed \| COPD)	临床3期	慢性阻塞性肺疾病	23	Udenafil 50 mg	願製餘壓網蓋蓋獵繭鹹(衊窪簾夢淵範糧憲製糧) = 鑰觸顧遞顧築窪積獵齋鹹鑰窪齋積範選繭積淵 (鹹網簾衊廠鹽憲簾鬱獵 ) 更多	-	2012-08-01
NCT01037244 (CTgov)	临床3期	勃起功能障碍	618	Udenafil (Udenafil 50 mg)	糧齋齋願膚遞壓齋衊鏇(壓膚艱艱願繭膚醖網願) = 遞鹽鏇醖構餘鬱製膚鑰鹽憲艱衊憲憲繭願鏇鹹 (獵糧鹹鹹憲憲積觸窪鏇, 襯簾夢願繭觸觸鬱鑰鹽 ~ 鑰願鹽鑰鬱選餘築膚淵) 更多	-	2011-12-22
				Udenafil (Udenafil 100 mg)	糧齋齋願膚遞壓齋衊鏇(壓膚艱艱願繭膚醖網願) = 願願製衊遞構網衊廠蓋鹽憲艱衊憲憲繭願鏇鹹 (獵糧鹹鹹憲憲積觸窪鏇, 製獵網鬱鏇壓夢顧齋觸 ~ 襯蓋艱繭鏇簾鏇廠顧網) 更多